NeoGenomics, Inc. (NASDAQ:NEO) is expected to report third quarter earnings results, before market open, on Tuesday 27th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.04 per share.
Looking ahead, the full year income are expected at $ 0.05 per share on the revenues of $ 452.04 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 464.00 million ~ $ 474.00 million
Click Here For More Historical Outlooks Of NeoGenomics, Inc.
Previous Quarter Performance
NeoGenomics, Inc. unveiled loss for the second quarter of $ 0.04 per share, from the revenue of $ 86.98 million. The quarterly revenues down 14.48 percent compared with the same quarter last year. According to street consensus, NEO was expected to report 2Q20 loss of $ 0.10 per share from revenue of $ 86.55 million. The bottom line results beat street analysts by $ 0.06 or 60.00 percent, at the same time, top line results outshined analysts by $ 0.43 million or 0.50 percent.
Stock Performance
Shares of NeoGenomics, Inc. traded low $ -1.12 or -2.64 percent on Friday, reaching $ 41.34 with volume of 616.10 thousand shares. NeoGenomics, Inc. has traded high as $ 42.58 and has cracked $ 40.65 on the downward trend
According to the previous trading day, closing price of $ 41.34, representing a 111.88 % increase from the 52 week low of $ 20.04 and a 4.76 % decrease over the 52 week high of $ 44.58.
The company has a market capital of $ 4.85 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 9th September 2020, initiated by Morgan Stanley at Overweight rating, with $ 46.00 target price.
- On 28th August 2020, initiated by Guggenheim at Buy rating, with $ 46.00 target price.
Conference Call
NeoGenomics, Inc. will be hosting a conference call at 8:30 AM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neogenomics.com
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The companys laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
